Extensive pelvic lymph node dissection and radical prostatectomy in the treatment of locally advanced prostate cancer with 10 years experiences:a follow-up of 246 cases
Wang Yu,Sun Zhuolun,Li Tengcheng,Liu Xiaopeng,Li Ke,Hu Cheng,Fang Youqiang,Li Liaoyuan,Di Jinming,Gao Xin
DOI: https://doi.org/10.3877/cma.j.issn.1674-3253.2022.02.002
2022-01-01
Abstract:Objective:The long-term follow-up results of patients with locally advanced prostate cancer (LAPC) treated with laparoscopic extensive pelvic lymph node dissection combined with radical prostatectomy (ePLND+LRP) are still rare. This study reports 246 LAPC patients treated with ePLND+LRP from 2006 to 2020 in the Third Affiliated Hospital of Sun Yat-sen University.Methods:From October 2006 to October 2020, 246 LAPC patients with ePLND+LRP were enrolled in this study. The operation time, blood loss, duration of hospital stay and complications, oncology results, and adjuvant treatments occurred within 30 days after surgery were collected.Results:The median age was 70(65-74) years; the median PSA was 24(10-60) ng/ml. The median operation time, blood loss, and hospital stay were 217 minutes, 170 ml, and 7 days, respectively. In pathological staging, there were 28 cases (11.4%) in pT2, 117 cases (47.6%) in pT3a, 92 cases (37.4%) in pT3b, and 9 cases (3.7%) in pT4. The median number of lymph nodes dissected was 21(13-27), and the median number of positive lymph nodes was 2(1-3). 48(19.5%) and 31(12.6%) patients had positive lymph nodes and positive surgical margins. Thirty-eight(15.4%) patients experienced complications, of which 17 cases (6.9%) were classified as Clavien I, 19 cases (7.7%) were classified as Clavien II, and 2 cases (0.8%) were classified as Clavien III. The median follow-up time was 127.8 months, during the follow-up period, 23(9.3%), 219(89.0%), 59(24.0%), and 7(2.8%) patients received adjuvant radiotherapy (RT), hormone therapy (HT), and salvage lymph node dissection (sLND), salvage local treatment. The 10-year BCR-free survival and metastasis-free survival (MFS) rates were 58.5%(144/246) and 73.6%(181/246), respectively. Cancer-specific survival (CSS) and overall survival (OS) were 91.6% and 85.3%, respectively. The rate of urinary control at one year after operation was 96.7%.Conclusion:The ePLND+LRP treatment of LAPC has fewer complications and a good tumor control effect. It is safe and effective as the initial treatment of LAPC.